arrow
R

Robin Foà

Sapienza University of Rome
H指数:86
被引数:4.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Dynamics of in vivo immune remodeling in Ph+ all patients receiving frontline ponatinib and blinatumomab therapy

Ph+ ALL患者接受一线ponatinib和blinatumomab治疗后的体内免疫重塑动力学

2026-08-120
OA
Favorable outcomes after early allogeneic stem cell transplantation in adult early T-cell precursor acute lymphoblastic leukemia treated with the pediatric-inspired GIMEMA LAL1913 program. A Campus ALL study

成人早期T细胞前体急性淋巴细胞白血病患者在接受儿科启发式GIMEMA LAL1913方案治疗后,早期同种异基因干细胞移植的积极结果。Campus ALL研究

2026-07-160
PRE
Allogeneic stem cell transplantation in adult Ph-like acute lymphoblastic leukemia. Results from two consecutive GIMEMA protocols
2026-07-080
OA
Immunomodulatory effect of dasatinib plus blinatumomab versus ponatinib plus blinatumomab in newly diagnosed Ph+ acute lymphoblastic leukemia

达沙替尼联合blinatumomab与ponatinib联合blinatumomab在新诊断的Ph急性淋巴细胞白血病中的免疫调节作用

Leukemia
IF13.4
2026-01-220
PRE
Plasma metabolomics and ctDNA analysis in newly diagnosed diffuse large B-cell lymphoma: an exploratory study

新诊断弥漫性大B细胞淋巴瘤的血浆代谢组学和ctDNA分析:一项探索性研究

2026-01-010
OA
Real-life efficacy and safety of vemurafenib plus rituximab in relapsed or refractory hairy-cell leukemia: A multicenter Italian retrospective study (HCL-PG03R)

vemurafenib联合利妥昔单抗治疗复发或难治性毛细胞白血病的真实世界疗效与安全性:一项多中心意大利回顾性研究(HCL-PG03R)

2025-11-140
OAAI
Integration of [18F]FDG-PET radiomics with liquid biopsy improves outcome prediction in newly diagnosed diffuse large B-cell lymphoma

[18F] fdg-pet影像组学与液体活检的整合可改善新诊断的弥漫性大b细胞淋巴瘤的预后预测

Leukemia
IF13.4
2025-07-080
OAAI
BH3 mimetic drugs overcome the microenvironment-induced resistance to crizotinib in ALK+ anaplastic large cell lymphoma

BH3拟似物药物克服了微环境诱导的克唑替尼耐药性在ALK阳性间变性大细胞淋巴瘤中。

2025-07-050
OAAI
Immunomodulatory Effect of Dasatinib Plus Blinatumomab Versus Ponatinib Plus Blinatumomab in Newly Diagnosed Ph plus Acute Lymphoblastic Leukemia Patients

Dasatinib联合Blinatumomab与Ponatinib联合Blinatumomab在 newly diagnosed Ph plus acute lymphoblastic leukemia 患者中的免疫调节效应比较

BLOOD
IF23.1
2024-11-050
PRE
Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph plus ALL) in the Setting of the Gimema ALL2820 Trial

可测量残留病灶监测在Gimema ALL2820试验中针对费城染色体阳性急性淋巴细胞白血病(Ph plus ALL)的应用

BLOOD
IF23.1
2024-11-050
PRE
Outcome of 421 adult patients with Philadelphia-negative acute lymphoblastic leukemia treated under an intensive program inspired by the GIMEMA LAL1913 clinical trial: a Campus ALL study
2024-08-152
OAAI
Ponatinib alone or with chemo-immunotherapy in heavily pre treated Philadelphia-like acute lymphoblastic leukemia: a CAMPUS ALL real-life study
2024-08-010
OAAI
CD49d expression is included in a revised 4-factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real-world experience
2024-07-151
OAAI
10-day decitabine versus 3+7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3trial
2023-11-018
PRE